Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, T-Cell 1 Head and Neck Carcinoma 1 Glioblastoma 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1

Interventions

Temozolomide 69 Radiotherapy 30 Bevacizumab 24 Carboplatin 13 pembrolizumab 12 Radiation 11 Carmustine 8 Irinotecan 7 temsirolimus 6 Surgical Procedures, Operative 6 Radiosurgery 6 Erlotinib Hydrochloride 6 atezolizumab 5 Vorinostat 5 Sirolimus 5 Radiotherapy, Intensity-Modulated 5 Nivolumab 5 Lomustine 5 Everolimus 5 fludarabine 4 Radiotherapy, Conformal 4 Magnetic Resonance Spectroscopy 4 Cyclophosphamide 4 Aminolevulinic Acid 4 tipifarnib 3 Sorafenib 3 Paclitaxel 3 IL13-PE38 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Gemcitabine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Glioblastoma × Solutions × Clear all

NCT03233152 2025-11-21

GlitIpNi

Universitair Ziekenhuis Brussel

Phase 1/2 Active not recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡